The combination of various therapies such as chemotherapy with immunotherapy has demonstrated significant improvement in response rates. Of late, the FDA has also been approving more immunotherapy drugs for a variety of oncological disorders, which is likely to uplift the development of the esophageal cancer market. The market is touted to accrue revenue at an 8.7% CAGR from 2017 to 2023 (forecast period).
ALSO READ :https://www.techsite.io/p/1898814
Rated the sixth most common type of cancer affecting patients, esophageal cancer is responsible for numerous deaths worldwide. Tobacco and alcohol consumption or certain dietary habits can lead to probabilities of attaining the disease.
Regional Analysis
Region-wise, the esophageal cancer market has been segmented into North America, the Middle East & Africa (MEA), Asia Pacific (APAC), and Europe.
With numerous cases of esophageal cancer, North America has commanded the leading position in the global esophageal cancer market. The population of the region is highly addicted to tobacco, which remains among the prime causes of esophageal cancer. High government support, high healthcare expenditure, and a favorable reimbursement landscape are providing impetus to the growth of the North American market. The US has a major contribution to make in the North America market. Robust healthcare infrastructure and the presence of a wide population base supports the growth of the market.
Segmentation Analysis
The global esophageal cancer market has been segmented based on type, phase, and treatment.
By type, the esophageal cancer market has been segmented into esophageal squamous-cell carcinoma, esophageal adenocarcinoma, and others. The esophageal squamous-cell carcinoma segment is predicted to gain significant revenue in the coming years. It held close to 65% market share in 2016.
Intensive R&D activities in Europe is driving the growth of the esophageal cancer market in Europe. The expansion of the APAC market can be attributed to the surging incidence rate of esophageal cancer and large unmet needs in the region.
The global esophageal cancer market is growing considerably and is expected to reach USD 1000.1 Million by the end of 2023 and progress at a CAGR of 8.7% over the forecast period of 2017-2023, reveals Market Research Future (MRFR) in an exhaustive study.
The market has been observing persistent growth on account of rising prevalence of esophageal cancer among the global population which results in diagnosis and treatment.
High consumption of alcohol and smoking habits among the mass drive the market growth as smoking and drinking expose consumers at more risk of developing esophageal cancer.
Moreover, the high prevalence of digestive disorders is also responsible for the growth of the market.
The rise in a number of clinical activities and rise in a number of approvals provided by FDA for novel drugs and therapies aimed at the treatment of esophageal cancer also adds fuel to the growth of the market.
By treatment, the market has been segmented into surgery, chemotherapy and radiotherapy and others.Regional Analysis:The comprehensive geographical study of the global esophageal market spans across North America, Europe, Asia Pacific, and the Middle East & Africa (MEA).
Market HighlightsThe Global Surgical Retractors Market held a market value of USD 1,103 Million in 2017 and is projected to grow at a CAGR of 7.8% over the forecast period.An increasing number of surgical procedures leading to increase demand of surgical retractors.
Surgical retractors are one of the important surgical instruments which is used to separate the edges of the wound or surgical incision.
Due to increasing prevalence of obesity across the globe many of the companies are in the race to introduce better treatment for obesity.
Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth.
As per the data by the Office for National Statistics, in 2016, the gross domestic expenditure on research and development (R) was Euro 33.1 billion (USD 35.2 billion) in the UK.
Europe is expected to hold the second-largest position in the global surgical retractors market owing to the presence of strong academic & research base and availability of funding for research in the European countries.
Global Merkel Cell Carcinoma Market Research Report: By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), Treatment (Surgery, Radiation Therapy, Chemotherapy), End User (Hospitals & Clinics, Diagnostic Centers) – Forecast till 2027Market HighlightsIncreasing prevalence of Merkel cell carcinoma and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period.
However, the high cost of therapeutics and related side effects along with the lack of awareness and low per capita healthcare expenditures in the developing economies restrains the market growth.
The chemotherapy segment is sub-segmented into etoposide, cisplatin, and others.
On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, research organization, and others.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5343Regional AnalysisThe Americas dominate the global Merkel cell carcinoma market.
Presence of a well-developed healthcare sector and high per capita healthcare expenditures provides favorable backgrounds for market growth within the region.
Followed by the Americas, Europe leads the Merkel cell carcinoma market.
Basal cell carcinoma is one of the most common types of skin cancers observed around the world.
Conventionally, the disease has been treated with procedures such as standard surgical excisions, and curettage.
The risk of contracting the disease increases among people who have immunosuppression issues, fair skin, genetic disorders, exposure to ultraviolet light, and a history of BCC.The global basal cell carcinoma treatment market is projected to grow at an impressive CAGR of 9 per cent through the forecast period till 2025.
This growth can be attributed to the increased investments being made by healthcare and pharmaceutical industries into the development of better drug formulations, with the aim of cutting down the risk of basal cell carcinoma.Increased Use of Contract Research Organizations and Radiotherapy Gain TractionCountries in the Asia Pacific and North America regions are expected to display a high potential for growth for the basal cell carcinoma treatment market, which can be attributed to the rising patient awareness about the ailment and the recent advancements and growing range of treatment options including Mohs micrographic surgery, superficial field therapies, and electrodessication.In addition, a number of contract research organizations such as the Skin Cancer Foundation have come up, which have been pushing to increase awareness about the cancer, while also creating training programs for health care professionals for the correct implementation of new treatment options.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=4366Further, countries in the Asia Pacific region are expected to generate substantial revenue generation opportunities, in comparison numerous regions in such treatment markets on a global scale.
Contract research organizations are also providing new information and insight on treatments such as radiotherapy, which is substantially influencing the landscape of the market.Non-invasive Treatments are Major ContributorsWhile surgical treatments have been the most popular conventionally, patients are increasingly preferring to opt for non-invasive treatments such as superficial radiation therapy (SRT) as such treatment results in lesser risk of complications.In addition, delays in treating basal cell carcinoma can result in issues with bone, skin, and muscle damage, which has also contributed to the increased adoption of SRT over the increasingly impractical practice of radiotherapy.In addition, the older conventional methods and machines of SRT has become obsolete, and create challenges in terms of operations and maintenance.
Consequently, modernization of these equipment is working as a catalyst to the growth of the global basal cell carcinoma market.SRT has been found to result in better outcomes for the patients, as treatments can only impact cancer cells, leaving healthy cells unaffected.
Market HighlightsCell counting market is expected to witness positive growth in future as it has wide range of applications in research institutes, hospitals, biotechnology and pharmaceuticals companies and it an important tool in research, drug discovery and biopharmaceutical applications.
Increasing prevalence of cancer and rising geriatric population are major driver for the market growth.
Furthermore, factors responsible for the growth of the cell counting market in Asia Pacific are rising awareness regarding prevalence of disease such as cancer and other lifestyle diseases and improvement in healthcare facilities.
High cost of cell counting instruments may create an obstacle for the market growth.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/628Asia Pacific cell counting market is expected to grow at a CAGR of 10.5% during forecast period 2017 to 2023.Asia-Pacific Cell Counting Market Players:Key players in cell counting market are Bio-Rad Laboratories Inc. (U.S), General Electric Company (U.S), Agilent Technologies (U.S), PerkinElmer Inc. (U.S), Tecan Trading AG (Switzerland), BioTek Instruments, Inc. (U.S), Danaher (U.S), Merck KGaA (U.S).Segmentation:The Asia Pacific cell counting market is segmented on the basis on instruments used for cell counting which are spectrophotometer, cell counter, hemocytometer, flow cytometer, hematology analyzer, microscope and other instruments.
On the basis of application of cell counting which includes cell structure study and cell analysis, quality control, cell viability, proliferation, signaling, identification, single cell analysis and other applications.
Regional Analysis:Asia Pacific cell counting market consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia Pacific.
